Statements (70)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
subcutaneous injection |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2009 |
| gptkbp:ATCCode |
L04AC05
|
| gptkbp:brand |
gptkb:Stelara
|
| gptkbp:CASNumber |
815610-63-0
|
| gptkbp:contraindication |
active serious infection
hypersensitivity to ustekinumab |
| gptkbp:developedBy |
gptkb:Janssen_Biotech
|
| gptkbp:halfLife |
15-45 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
ustekinumab
|
| gptkbp:KEGGID |
D08928
|
| gptkbp:legalStatus |
prescription only
patented |
| gptkbp:macromoleculeType |
gptkb:IgG1_kappa
|
| gptkbp:mechanismOfAction |
inhibits IL-12 and IL-23 cytokines
|
| gptkbp:molecularWeight |
148,600 Da
|
| gptkbp:monitors |
liver function tests
complete blood count tuberculosis screening |
| gptkbp:origin |
human monoclonal antibody
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:prescribes |
adults
children over 6 years (for some indications) |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:PubChem_CID |
CHEMBL1201836
11671467 DB06174 |
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
gptkb:sinusitis
gptkb:depression bronchitis fever nausea vomiting diarrhea pain abdominal pain dizziness fatigue headache hypertension back pain muscle pain pruritus cough rash insomnia injection site reactions arthralgia cellulitis upper respiratory tract infection increased risk of infection nasopharyngitis pharyngitis |
| gptkbp:target |
gptkb:interleukin-12
gptkb:interleukin-23 |
| gptkbp:UNII |
Q1J9J9Y1N6
|
| gptkbp:usedFor |
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis ulcerative colitis psoriasis |
| gptkbp:bfsParent |
gptkb:Stelara
|
| gptkbp:bfsLayer |
6
|